Last reviewed · How we verify
Instituto Valenciano de Infertilidade de Lisboa — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Vaginal micronized progesterone | Vaginal micronized progesterone | marketed | Progestin | Progesterone receptor (PR) | Reproductive/Fertility |
Therapeutic area mix
- Reproductive/Fertility · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bayer · 1 shared drug class
- Baylor Research Institute · 1 shared drug class
- Bio Meds Pharmaceutica Ltda · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
- Exeltis Usa Inc · 1 shared drug class
- Fdn Consumer · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Instituto Valenciano de Infertilidade de Lisboa:
- Instituto Valenciano de Infertilidade de Lisboa pipeline updates — RSS
- Instituto Valenciano de Infertilidade de Lisboa pipeline updates — Atom
- Instituto Valenciano de Infertilidade de Lisboa pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Instituto Valenciano de Infertilidade de Lisboa — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-valenciano-de-infertilidade-de-lisboa. Accessed 2026-05-16.